New Treatment Options for Relapsed/Recurrent DLBCL: Impact on Sequencing Therapeutic Choices : Episode 9

Opinion

Video

July 29, 2024

Risk of Secondary Malignancies in Heavily Pre-Treated Population

Author(s):

Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Elizabeth Budde, MD, PhD

A panel of experts discuss risk of secondary malignancies in heavily pre-treated populations.

EP: 1.Navigating Second-Line Treatments and CAR T-Cell Therapy for DLBCL: Insights from Dr. Budde and Dr. Lunning

EP: 2.Dr Locke, Dr Hunter, Dr Lunning Share Referral Patterns in Their Practices

EP: 3.Dr Locke Shares Key Takeaways from ZUMA-7 and TRANSFORM Studies

EP: 4.Dr Gordon Shares Key Takeaways from ALYCANTE and PILOT for 2L CAR T-cell Transplant-Ineligible Population

EP: 5.Dr Hunter Shares Key Takeaways from L-MIND 5-Year Data and RE-MIND2 Study

EP: 6.Panel Discuses Use of CD19 Bispecifics in Sequencing

EP: 7.Panel Discusses Challenges with CAR T Therapy in R/R DLBCL, Particularly Around T-cell Exhaustion

EP: 8.Current Approach to Bridging Therapy in R/R DLBCL

EP: 9.Risk of Secondary Malignancies in Heavily Pre-Treated Population

EP: 10.Management of CRS and ICANS with CAR T-cell Therapy

EP: 11.Third-line Treatment Options for DLBCL After CAR T-cell Therapy or ASCT in Second-line

EP: 12.Contemporary Sequencing CD20xCD3 Bispecific Antibody R/R DLBCL Who Have progressed beyond CAR T-cell therapy

EP: 13.Bispecific therapy – treatment setting and management of short-term adverse events

EP: 14.Bispecific therapy – management of long-term adverse events in the community setting

EP: 15.Practice Patterns and Real Use of Epcoritamab and Glofitamab

EP: 16.Disparities in access to newer or expensive treatments, unmet needs in the treatment of DLBCL

Video content above is prompted by the following:

In R/R DLBCL, how do you select among the available options in the secondline setting?

Related Videos

Related Content

Related Content

Latest Conference Coverage

Active Monitoring Is Noninferior to Guideline Concordant Care in Low-Risk DCIS

Postoperative Radiation Therapy Improves HRQOL, Safety in Early-Stage HR+/HER2– Breast Cancer

Baseline ctDNA Is Associated With Larger Pathological Tumors in HR+ Early Breast Cancer

Elacestrant Improves Real-World Time to Next Treatment or Treatment Discontinuation in ESR1+ HR+/HER2– Breast Cancer

View More Latest Conference Coverage

Editorial Board

MJH Life Sciences brands

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2024 MJH Life Sciences

All rights reserved.